Insider Selling: Zimmer Biomet (NYSE:ZBH) Insider Sells $528,978.45 in Stock

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) insider Kevin Thornal sold 5,691 shares of the business’s stock in a transaction that occurred on Friday, September 11th. The shares were sold at an average price of $92.95, for a total transaction of $528,978.45. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Zimmer Biomet Stock Performance

NYSE ZBH opened at $94.33 on Friday. The company has a current ratio of 1.69, a quick ratio of 0.94 and a debt-to-equity ratio of 0.50. The firm has a market capitalization of $17.99 billion, a price-to-earnings ratio of 22.95, a P/E/G ratio of 1.83 and a beta of 0.47. The firm’s 50 day simple moving average is $96.15 and its 200 day simple moving average is $91.38. Zimmer Biomet Holdings, Inc. has a 1 year low of $79.12 and a 1 year high of $106.88.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings data on Wednesday, August 5th. The medical equipment provider reported $2.07 EPS for the quarter, beating the consensus estimate of $2.01 by $0.06. The business had revenue of $2.18 billion during the quarter, compared to the consensus estimate of $2.13 billion. Zimmer Biomet had a net margin of 9.48% and a return on equity of 13.12%. The company’s revenue was up 4.8% on a year-over-year basis. During the same period in the previous year, the business earned $2.07 earnings per share. Zimmer Biomet has set its FY 2026 guidance at 8.470-8.590 EPS. As a group, research analysts expect that Zimmer Biomet Holdings, Inc. will post 8.54 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be issued a $0.24 dividend. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.0%. Zimmer Biomet’s dividend payout ratio is 23.36%.

Institutional Trading of Zimmer Biomet

Institutional investors and hedge funds have recently bought and sold shares of the stock. Main Management ETF Advisors LLC increased its holdings in shares of Zimmer Biomet by 1.0% in the fourth quarter. Main Management ETF Advisors LLC now owns 10,962 shares of the medical equipment provider’s stock valued at $986,000 after purchasing an additional 112 shares during the last quarter. Citizens National Bank Trust Department boosted its stake in Zimmer Biomet by 17.6% during the first quarter. Citizens National Bank Trust Department now owns 941 shares of the medical equipment provider’s stock worth $85,000 after buying an additional 141 shares during the last quarter. TD Private Client Wealth LLC grew its holdings in Zimmer Biomet by 15.3% in the 4th quarter. TD Private Client Wealth LLC now owns 1,152 shares of the medical equipment provider’s stock valued at $104,000 after buying an additional 153 shares in the last quarter. Leonteq Securities AG increased its stake in shares of Zimmer Biomet by 5.3% in the 1st quarter. Leonteq Securities AG now owns 3,062 shares of the medical equipment provider’s stock worth $277,000 after acquiring an additional 153 shares during the last quarter. Finally, Envestnet Portfolio Solutions Inc. increased its stake in shares of Zimmer Biomet by 5.5% in the 4th quarter. Envestnet Portfolio Solutions Inc. now owns 3,133 shares of the medical equipment provider’s stock worth $282,000 after acquiring an additional 162 shares during the last quarter. 88.89% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on ZBH shares. Needham & Company LLC reaffirmed a “hold” rating on shares of Zimmer Biomet in a report on Wednesday, August 5th. UBS Group restated a “buy” rating and issued a $120.00 target price on shares of Zimmer Biomet in a research report on Thursday, August 6th. Sanford C. Bernstein boosted their target price on shares of Zimmer Biomet from $91.00 to $93.00 and gave the stock a “market perform” rating in a research note on Thursday, August 6th. Weiss Ratings upgraded shares of Zimmer Biomet from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday. Finally, Canaccord Genuity Group increased their price target on Zimmer Biomet from $83.00 to $100.00 and gave the company a “hold” rating in a research note on Monday, August 10th. Six investment analysts have rated the stock with a Buy rating, fourteen have given a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $103.00.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc (NYSE:ZBH) is a medical technology company that develops, manufactures and markets products designed to treat musculoskeletal conditions. Its portfolio includes orthopedic implants and related systems for hip, knee, shoulder and other joint replacements, as well as products used in sports medicine, extremity care and trauma procedures.

The company also provides robotic- and computer-assisted surgical technologies, digital solutions and other tools intended to support orthopedic procedures and patient care.